Influenza, commonly known as the flu, is an infectious disease that can cause severe illness and even death. It’s important that any suspected case of the flu is properly diagnosed and treated as soon as possible. Here’s a look at the different ways that influenza can be diagnosed.
Currently, Influenza Diagnostics Market is projected to reach USD 1.1 billion by 2026 from USD 0.8 billion in 2021, at a CAGR of 7.7%. Rising demand for rapid disease diagnosis, increasing prevalence of influenza and growth in influenza research for diagnostic technologies are among the other factors. Emerging economies such as India and Japan are providing lucrative opportunities for the players operating in the influenza diagnostics market.
The most common way to diagnose influenza is through a physical examination. During the physical exam, the doctor will look for symptoms such as fever, chills, body aches, sore throat, headache, and coughing. If the doctor suspects the flu, they may order a lab test to confirm the diagnosis.
The lab test most commonly used to diagnose influenza is the rapid influenza diagnostic test (RIDT). This test looks for proteins found in the flu virus and can provide results within 15 minutes. It’s important to note, however, that this test is not 100% accurate and false-positive and false-negative results are possible.
In some cases, a more accurate test known as the reverse transcription-polymerase chain reaction (RT-PCR) may be used to diagnose influenza. This test requires a sample of mucus from the nose or throat and can detect the virus’s genetic material. This test is much more accurate than the RIDT and can give results within a few hours.
Once a diagnosis of influenza is confirmed, the doctor will recommend a course of treatment. This may include rest, fluids, over-the-counter medications, and antiviral medications. In some cases, hospitalization may be necessary.
It’s important to remember that early diagnosis and treatment of influenza can help reduce the severity and duration of the illness. If you have any symptoms that could be related to the flu, it’s important to seek medical attention right away.
Request for assumptions & how numbers were triangulated.
https://www.marketsandmarkets.com/requestsampleNew.asp?id=222985562
Molecular Diagnostic Tests segment to register the highest growth rate during the forecast period
The influenza diagnostics market is segmented into traditional diagnostic test (rapid influenza diagnostic tests, viral culture tests, direct fluorescent antibody test, serological tests) and molecular diagnostic tests (polymerase chain reaction, isothermal nucleic acid amplification tests(transcription-mediated amplification-based assay, loop-mediated isothermal amplification-based assay, nucleic acid sequence-based amplification tests, other isothermal nucleic acid amplification tests) and other molecular diagnostic tests. In 2020, the molecular diagnostic tests segment accounted for the highest growth rate. Factors such as the rising demand for rapid disease diagnosis drive this market and growth in influenza research for diagnostic technologies.
North America is the largest regional market for influenza diagnostics market
The global influenza diagnostics market is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the influenza diagnostics market. The large share of this region can be attributed to growth in influenza research for diagnostic technologies and rising demand for rapid disease diagnosis.
The influenza diagnostics market is expected to witness a significant growth over the forecast period owing to the rising prevalence of influenza and the increasing demand for rapid and accurate diagnosis. Factors such as the growing awareness among people, availability of advanced testing systems, and increasing government initiatives are some of the major drivers of the market. Additionally, technological advancements in the field of diagnostics and increasing investments in research and development activities are expected to boost the market growth.
However, the lack of skilled professionals and the high cost of diagnostic tests may hinder the growth of the market. Nevertheless, the growing demand for point-of-care testing and the introduction of advanced testing systems are expected to create lucrative opportunities for the market players.
Download an Illustrative Overview:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=222985562
Recent Developments
- In May 2021 Becton, Dickinson and Company (US) received FDA approval for the BD Veritor Plus System, which is used to detect SARS-CoV-2, influenza A, and influenza B.
- In March 2021, Abbott Laboratories, Inc. (US) received emergency use authorization (EUA) from the FDA for a laboratory PCR assay that detects and differentiates SARS-COV-2, flu A, flu B, and RSV in one test.
- In February 2021, Becton, Dickinson and Company (US) received approval from the FDA for the emergency use authorization (EUA) for a new molecular diagnostic test for both SARS-CoV-2 and influenza A+B.
Content Source:
https://www.marketsandmarkets.com/Market-Reports/influenza-diagnostic-market-222985562.html
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek